Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Masimo
So what: Revenue grew 3% to $104 million, yet profits fell to $0.24 a share from $0.27 in last year's third quarter. Analysts had expected the maker of blood-monitoring instruments to produce $0.27 a share on $109.7 million in revenue, according to data compiled by Yahoo! Finance. The message? Five-star rating or not, few medical device makers can deliver the way Intuitive Surgical
Now what: Unfortunately, the story didn't end there. Management compounded the miss by lowering its full-year forecast to $1.04 to $1.06 in per-share earnings on $436 million to $439 million in revenue. Both estimates were well off the bottom end of earlier guidance and what Wall Street expected. Does it matter? Would you buy shares of Masimo now that the stock trades for less than analysts' consensus long-term estimates for profit growth? Please weigh in using the comments box below.
Interested in more information about Masimo? Add it to your watchlist by clicking here.